The stock is in a powerful, sustained uptrend, evidenced by a staggering 94.11% gain over the past year. As of the latest close at $570.40, the price is trading at approximately 94% of its 52-week high of $607.89, indicating it is near the peak of its recent range and reflecting strong bullish momentum, though it also suggests the stock may be extended and vulnerable to a pullback. The stock's 1-month performance of +2.28% and 3-month performance of +21.49% demonstrate that short-term momentum remains robust and is accelerating relative to the longer-term trend, with the 3-month return significantly outpacing the S&P 500's 4.14% gain. However, the 1-month relative strength of -9.96 versus the market hints at a recent period of consolidation or slight underperformance following the explosive move in late March, which saw the price jump from $522.83 to $592.98 in a single day on March 30th. Key technical support lies at the 52-week low of $272.12, though a more relevant near-term support zone is likely around the $520-$530 area, which was the consolidation range prior to the late-March breakout. Immediate resistance is at the 52-week high of $607.89; a decisive breakout above this level could signal a continuation of the uptrend, while a failure could lead to a retest of lower support. The stock's beta of 0.75 indicates it has been 25% less volatile than the broader market over the measured period, which is notable given its large price appreciation and suggests the moves have been driven by fundamental catalysts rather than speculative frenzy.

United Therapeutics exhibits a stable revenue trajectory with modest growth, as Q4 2025 revenue of $790.2 million represented a 7.38% year-over-year increase. Sequentially, revenue has been remarkably steady, fluctuating between $794.4 million and $799.5 million over the prior three quarters of 2025, indicating a mature, plateauing core business that is now poised for potential expansion from new indications. The company's flagship product, Tyvaso, is the clear growth driver, generating $464.3 million in the latest period, which dwarfs the contributions from Remodulin ($128M), Orenitram ($121.2M), and other therapies. The company is highly profitable, with Q4 2025 net income of $364.3 million and an impressive net margin of 46.1%. Gross margins are exceptional at 86.91% for the quarter, consistent with the trailing gross margin of 87.92%, reflecting the premium pricing power of its specialty pharmaceutical portfolio. Operating margins are also strong at 46.89%, though the Q4 operating income of $356.7 million resulted in a slightly lower operating margin of 45.14%, showing some quarterly variability in expense management. The balance sheet is exceptionally strong with zero debt, as indicated by a debt-to-equity ratio of 0, and robust liquidity evidenced by a current ratio of 6.60. The company generates substantial cash, with trailing twelve-month free cash flow of $1.04 billion, providing ample internal resources to fund R&D, business development, and shareholder returns without leverage. Return on equity is healthy at 18.81%, demonstrating efficient use of shareholder capital.